These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27626058)

  • 1. Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity.
    Hirvinen M; Capasso C; Guse K; Garofalo M; Vitale A; Ahonen M; Kuryk L; Vähä-Koskela M; Hemminki A; Fortino V; Greco D; Cerullo V
    Mol Ther Oncolytics; 2016; 3():16002. PubMed ID: 27626058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
    Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering Oncolytic Vaccinia Virus to redirect Macrophages to Tumor Cells.
    Cao F; Nguyen P; Hong B; DeRenzo C; Rainusso NC; Rodriguez Cruz T; Wu MF; Liu H; Song XT; Suzuki M; Wang LL; Yustein JT; Gottschalk S
    Adv Cell Gene Ther; 2021 Apr; 4(2):. PubMed ID: 33829146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Oncolytic Vaccinia Viruses Expressing Human β-Defensin 2 Enhance Anti-tumor Immunity.
    Sun T; Luo Y; Wang M; Xie T; Yan H
    Mol Ther Oncolytics; 2019 Jun; 13():49-57. PubMed ID: 31011627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
    Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
    Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oncolytic vaccinia virus expressing CD40L (CD40L-VV) inhibits colorectal cancer cell growth and enhances anti-tumor activity of T cells in tumor-bearing mice].
    Liu D; Ma J; Ding B; Zhou H
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):602-607. PubMed ID: 34140071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus Neutralization Escape while Preserving Oncolytic Function.
    Nakatake M; Kurosaki H; Kuwano N; Horita K; Ito M; Kono H; Okamura T; Hasegawa K; Yasutomi Y; Nakamura T
    Mol Ther Oncolytics; 2019 Sep; 14():159-171. PubMed ID: 31236440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient inhibition of neutrophil functions enhances the antitumor effect of intravenously delivered oncolytic vaccinia virus.
    Zhou D; Xu W; Ding X; Guo H; Wang J; Zhao G; Zhang C; Zhang Z; Wang Z; Wang P; Lu L; Yuan M
    Cancer Sci; 2024 Apr; 115(4):1129-1140. PubMed ID: 38351514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent expression of
    Ma J; Jin C; Čančer M; Wang H; Ramachandran M; Yu D
    Mol Ther Oncolytics; 2021 Jun; 21():356-366. PubMed ID: 34141872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors.
    Wei M; Zuo S; Chen Z; Qian P; Zhang Y; Kong L; Gao H; Wei J; Dong J
    Front Immunol; 2022; 13():1017574. PubMed ID: 36451817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.
    John LB; Howland LJ; Flynn JK; West AC; Devaud C; Duong CP; Stewart TJ; Westwood JA; Guo ZS; Bartlett DL; Smyth MJ; Kershaw MH; Darcy PK
    Cancer Res; 2012 Apr; 72(7):1651-60. PubMed ID: 22315352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.
    Fend L; Remy-Ziller C; Foloppe J; Kempf J; Cochin S; Barraud L; Accart N; Erbs P; Fournel S; Préville X
    Oncoimmunology; 2016 Feb; 5(2):e1080414. PubMed ID: 27057460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development.
    Ho TY; Mealiea D; Okamoto L; Stojdl DF; McCart JA
    Mol Ther Oncolytics; 2021 Sep; 22():85-97. PubMed ID: 34514091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innate immunity to viruses: control of vaccinia virus infection by gamma delta T cells.
    Selin LK; Santolucito PA; Pinto AK; Szomolanyi-Tsuda E; Welsh RM
    J Immunol; 2001 Jun; 166(11):6784-94. PubMed ID: 11359837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.
    Wang LC; Lynn RC; Cheng G; Alexander E; Kapoor V; Moon EK; Sun J; Fridlender ZG; Isaacs SN; Thorne SH; Albelda SM
    Mol Ther; 2012 Apr; 20(4):736-48. PubMed ID: 22008913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
    Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
    Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12.
    Kurokawa C; Agrawal S; Mitra A; Galvani E; Burke S; Varshine A; Rothstein R; Schifferli K; Monks NR; Foloppe J; Silvestre N; Quemeneur E; Demeusoit C; Kleinpeter P; Sapra P; Barrett C; Hammond SA; Kelly EJ; Laliberte J; Durham NM; Oberst M; Broggi MAS
    Mol Ther Oncol; 2024 Mar; 32(1):200758. PubMed ID: 38596304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.
    Kim SY; Kang D; Choi HJ; Joo Y; Kim JH; Song JJ
    Oncotarget; 2017 Feb; 8(9):15858-15877. PubMed ID: 28178658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.